Evotec AG (FSE:EVT) has entered into a ‘multi-year integrated drug discovery alliance’ with Genentech, a subsidiary of Roche Group (SWX:RO, SIX:ROG, PINK:RHHBY), to discover novel small molecule therapeutics.
Evotec will provide its drug discovery platform and disease biology expertise against targets nominated by Genentech. The agreement includes assay development and high throughput screening, medicinal chemistry and structural biology.
Evotech specializes in the discovery of novel small molecule drugs and has considerable experience in the areas of neuroscience, pain, oncology and inflammation. Genetech’s focus is the discovery, development and commercialization of medicines for serious or life threatening conditions.
Commercial details were not released.
"We are proud that Genentech, one of the premier biopharmaceutical companies worldwide, has selected Evotec's scientists and innovative drug discovery platform to support their research efforts,” Dr. Werner Lanthaler, CEO of Evotec, commented.